Clinical trial results are a major driver of biotech stock prices. The failure of Vir Biotechnology's Phase 2 trial for Vir-2482 to meet its primary and secondary efficacy endpoints is a significant setback, which could negatively impact investor sentiment and the company's stock price in the short term.